The global Meperidine (Demerol) Market is projected to reach $563.7 million by 2032

From GlobeNewswire: 2025-04-21 11:00:00

The global Meperidine (Demerol) Market is projected to grow from US$ 507.9 million in 2025 to US$ 563.7 million by 2032, with a CAGR of 1.5%. North America leads the market, while Asia Pacific follows due to rising pain conditions. Side effects and alternatives may limit market growth despite a rise in surgical procedures.

The tablets segment is expected to reach USD 284.42 million in 2025 due to patient preference. Anesthesia applications dominate the market, with retail pharmacies leading in distribution channels. North America is expected to hold half of the market share in 2025, with Asia Pacific following through 2032.

Increasing chronic pain prevalence globally is driving growth in the Meperidine (Demerol) market. However, potential side effects and the shift towards safer alternatives like fentanyl may hinder market growth. The rise in surgical procedures and the aging population are creating growth opportunities for Meperidine manufacturers.

Key companies in the Meperidine (Demerol) market include Hikma Pharmaceuticals, Pfizer, Vintage Pharmaceuticals, and more. Recent developments include Pfizer’s acquisition of Abzena’s manufacturing facility and Hikma Pharmaceuticals’ acquisition of Custopharm Inc. The market trends include the availability of cost-effective generic versions and the development of abuse-deterrent formulations.

The global Meperidine (Demerol) Market is set to witness growth driven by factors like acute and chronic pain conditions, surgical procedures, and the aging population. However, side effects and the transition to safer alternatives may limit market growth. Companies are focusing on innovative strategies to address market challenges.



Read more at GlobeNewswire: Meperidine (Demerol) Market Size to Reach $563.7 Million,